Following years of hard work, we are finally moving from words to action. In December 2017, we received the CE approval for the TetraGraph system and the OnZurf Probe. Commercialization has started, and we have delivered our first systems to customers. Our monitoring solutions are based on many years of research and development and we have a strong team and a number of distributor and license agreements in place. Market demand and driving forces are clear and we focus on taking the lead in the multi-billion market for peri- and post-operative monitoring.
To accelerate the international market roll-out, today we have announced a proposed new issue of SEK 25 million, directed to among others the new institutional shareholder Segulah. The issue gives us room for maneuver and we welcome another strong and long-term owner in the company. The issue allows us to accelerate market rollout and it strengthens our position in negotiations with additional potential strategic partners.
The driving forces for our products are significant. This was highlighted not least, when the issue of patient safety and the necessary measures to reduce complications after surgery was given ample room at the annual Society of Anesthesiologists (ASA) – the world’s largest anesthetic-related meeting where the most influential and significant individuals in anesthesiology, pain medication and medical care gathered.
Over 70 million patients undergo surgery every year using anesthesia and muscle relaxants. Research has clearly shown that over 30 percent of postoperative complications are due to the lack of objective monitoring to assess when it is safe to wake and extubate the patient. TetraGraph meets the needs and is a unique system developed to help reduce postoperative complications with a cost-effective and user-friendly solution.
After the reporting period, and in addition to our previous distribution and license agreements, we signed a license agreement with Philips. This is a strategically important agreement that enables TetraGraph to be integrated with Philips global patient monitoring systems.
Now we look forward to continue reporting on Senzime’s progress in 2018.
Uppsala, Febraury 2018
Lena Söderström, CEO of Senzime AB (publ)